By: IPP Bureau
Last updated : November 30, 2025 6:57 pm
Soficitinib is a potent and selective TYK2 inhibitor under development for multiple T-cell mediated autoimmune disorders
InnoCare Pharma, a leading biopharmaceutical company specializing in cancer and autoimmune therapies, announced that the first patient has been dosed in the global Phase II clinical trial of its novel TYK2 inhibitor, Soficitinib (ICP-332), targeting prurigo nodularis in China.
Soficitinib is a potent and selective TYK2 inhibitor under development for multiple T-cell mediated autoimmune disorders, including atopic dermatitis, vitiligo, urticaria, and prurigo nodularis. TYK2 plays a pivotal role in the JAK-STAT signaling pathway, which drives inflammatory disease processes.
Prurigo nodularis, a chronic inflammatory skin condition, is marked by intense itching and nodules that severely impact patients’ quality of life. Soficitinib works by blocking cytokine signaling pathways linked to itch and inflammation—such as IL-4, IL-13, and IL-31—reducing neurogenic itch responses and controlling skin inflammation.
The disease affects an estimated 10 million people worldwide, with the global market valued at US$2 billion in 2024 and projected to reach US$3 billion by 2034.
Dr Jasmine Cui, Co-founder, Chairwoman, and CEO of InnoCare, said, "InnoCare's pipeline under development now covers ten major autoimmune diseases, with a particular focus on dermatological conditions. The Phase II clinical study of Soficitinib for moderate-to-severe atopic dermatitis demonstrated outstanding efficacy and a strong safety profile."
"The data has been released as a late-breaking oral presentation at the American Academy of Dermatology (AAD) Annual Meeting. We are accelerating global clinical development to bring innovative therapies to more autoimmune patients as early as possible.”
This milestone marks a significant step forward for InnoCare’s global clinical program, highlighting the company’s commitment to delivering novel therapies for autoimmune and dermatological diseases.